Article Listing - Australia’s TGA approves Biogen’s Fampyra to improve MS patients walking ability

GLAXO CHIEF ON PHARMA INDUSTRY, PUBLIC NEEDS

16 March 1992

Unlike other high-technology, science-based industries, pharmaceuticals are unique as to marketing methods since they are not promoted direct to the...

ARTHRITIS "NEGLECTED" IN THE UK

16 March 1992

Although arthritis is estimated to affect about 20 million people in the UK, it is considered a neglected disease. Furthermore,...

REPLIGEN'S rPF4

16 March 1992

Massachusetts-based Repligen Corp has established a partnership to support the $45 million cost of the development of its recombinant platelet...

NEW PRODUCT PHASE FOR BRITISH BIO-TECH

16 March 1992

British-biotechnology Group will look back on 1991 as a milestone year in the company's history, according to chairman Brian Richards,...

UPJOHN "DOWNGRADE"

16 March 1992

Because of concerns regarding side effects and their impact on the sales of Upjohn's sedative Halcion (triazolam), now around $260...

ITALY'S MENARINI TO INVEST ABROAD

16 March 1992

Italian pharmaceutical concern Menarini has given up on its scheme to set up a plant on the island of Elba,...

STOCK MARKET COMMENTARY: NEW YORK

16 March 1992

NEW YORK: saw the Dow Jones move down for nearly the whole of the reporting week, closing on a subdued...

STOCK MARKET COMMENTARY: TOKYO

16 March 1992

TOKYO: stocks declined in a narrow trading range last week. Although volume remained low, the market did not have enough...

WYETH LTD/LTEE: SEAN FLYNN

16 March 1992

- Wyeth Ltd/Ltee of Canada has named Sean Flynn to the position of product manager for the company's line of...

ROUSSEL-UCLAFS MIFEGYNE

16 March 1992

- Roussel-Uclaf's progesterone antagonist abortifacient product Mifegyne (mifepristone) is to be tested as a first-line therapy for breast cancer in...

Showing 94671-94680 of 95360 articles